News

Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.

Catch up on coverage from the third day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

The study demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.

Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.

Delgocitinib cream offers a safe, low-systemic-exposure option for chronic hand eczema, according to a poster from the Elevate-Derm conference.

Affordable at-home treatments, including microneedling and benzoyl peroxide, were top pearls at Chilukuri's Elevate-Derm session.

The TRACE study showed tralokinumab reduced genital AD severity and improved quality of life within 3 months of treatment.

Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.

In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.

Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.

APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.

A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.

Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Mark Gimbel, MD, and Whitney High, MD, presented complex cases that underscore the critical need for comprehensive approaches in diagnosing melanocytic lesions.

Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.

Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.

Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.

Share with us the topics you want to learn more about at Elevate-Derm West.

The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.

Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.

The novel systemic review compared results and adverse events associated with various treatment methods.

These findings can help clinicians better treat the psychosocial factors associated with the disease.

We want to know: Will you be attending the conference in Scottsdale later this week?

A post hoc analysis of OLYMPIA 1 and 2 trial data found significant improvement in the first 14 days of treatment.

The target action review date has been pushed to March 12, 2025.

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Researchers noted that ethical use of AR and VR in cosmetic care requires balancing technological benefits with patient safety and privacy.

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.